Literature DB >> 22098355

Advances in HIV microbicide development.

Joanna S Olsen1, David Easterhoff, Stephen Dewhurst.   

Abstract

There is an urgent need control the spread of the global HIV pandemic. A microbicide, or topical drug applied to the mucosal environment to block transmission, is a promising HIV prevention strategy. The development of a safe and efficacious microbicide requires a thorough understanding of the mucosal environment and its role in HIV transmission. Knowledge of the key events in viral infection identifies points at which the virus might be most effectively targeted by a microbicide. The cervicovaginal and rectal mucosa play an important role in the innate defense against HIV, and microbicides must not interfere with these functions. In this review, we discuss the current research on HIV microbicide development.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22098355      PMCID: PMC3953563          DOI: 10.4155/fmc.11.153

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  131 in total

1.  Presence of secretory leukocyte protease inhibitor in human endometrium and first trimester decidua suggests an antibacterial protective role.

Authors:  A E King; H O Critchley; R W Kelly
Journal:  Mol Hum Reprod       Date:  2000-02       Impact factor: 4.025

Review 2.  Targeting early infection to prevent HIV-1 mucosal transmission.

Authors:  Ashley T Haase
Journal:  Nature       Date:  2010-03-11       Impact factor: 49.962

3.  Progesterone directly and indirectly affects perforin expression in cytolytic cells.

Authors:  G Laskarin; N Strbo; V Sotosek; D Rukavina; Z Faust; J Szekeres-Bartho; E R Podack
Journal:  Am J Reprod Immunol       Date:  1999-11       Impact factor: 3.886

Review 4.  Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection.

Authors:  Zdenek Hel; Elizabeth Stringer; Jiri Mestecky
Journal:  Endocr Rev       Date:  2009-11-10       Impact factor: 19.871

5.  In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide.

Authors:  Lisa C Rohan; Bernard J Moncla; Ratiya Pamela Kunjara Na Ayudhya; Marilyn Cost; Yunda Huang; Fang Gai; Nicole Billitto; J D Lynam; Kara Pryke; Phillip Graebing; Nicole Hopkins; James F Rooney; David Friend; Charlene S Dezzutti
Journal:  PLoS One       Date:  2010-02-19       Impact factor: 3.240

6.  Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women.

Authors:  Annalene Nel; Shanique Smythe; Katherine Young; Karl Malcolm; Clare McCoy; Zeda Rosenberg; Joseph Romano
Journal:  J Acquir Immune Defic Syndr       Date:  2009-08-01       Impact factor: 3.731

7.  Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus.

Authors:  Samuel K Lai; Kaoru Hida; Shetha Shukair; Ying-Ying Wang; Anna Figueiredo; Richard Cone; Thomas J Hope; Justin Hanes
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

8.  Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, phase I study.

Authors:  John O'Loughlin; Iona Y Millwood; Helen M McDonald; Clare F Price; John M Kaldor; Jeremy R A Paull
Journal:  Sex Transm Dis       Date:  2010-02       Impact factor: 2.830

9.  Elevated elafin/trappin-2 in the female genital tract is associated with protection against HIV acquisition.

Authors:  Shehzad M Iqbal; Terry B Ball; Pauline Levinson; Lillian Maranan; Walter Jaoko; Charles Wachihi; Brian J Pak; Vladimir N Podust; Kristina Broliden; Taha Hirbod; Rupert Kaul; Francis A Plummer
Journal:  AIDS       Date:  2009-08-24       Impact factor: 4.177

10.  Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials.

Authors:  Marla J Keller; Pedro M M Mesquita; N Merna Torres; Sylvia Cho; Gail Shust; Rebecca P Madan; Hillel W Cohen; Julie Petrie; Tara Ford; Lydia Soto-Torres; Albert T Profy; Betsy C Herold
Journal:  PLoS One       Date:  2010-01-22       Impact factor: 3.240

View more
  4 in total

1.  Structure and Glycan Binding of a New Cyanovirin-N Homolog.

Authors:  Elena Matei; Rohan Basu; William Furey; Jiong Shi; Conor Calnan; Christopher Aiken; Angela M Gronenborn
Journal:  J Biol Chem       Date:  2016-07-07       Impact factor: 5.157

2.  Evaluation of PD 404,182 as an anti-HIV and anti-herpes simplex virus microbicide.

Authors:  Ana M Chamoun-Emanuelli; Michael Bobardt; Bernard Moncla; Marie K Mankowski; Roger G Ptak; Philippe Gallay; Zhilei Chen
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

3.  3-hydroxyphthalic anhydride-modified human serum albumin as a microbicide candidate against HIV type 1 entry by targeting both viral envelope glycoprotein gp120 and cellular receptor CD4.

Authors:  Minmin Li; Jiangman Duan; Jiayin Qiu; Fei Yu; Xiaoyan Che; Shibo Jiang; Lin Li
Journal:  AIDS Res Hum Retroviruses       Date:  2013-06-18       Impact factor: 2.205

4.  Gardiquimod: a Toll-like receptor-7 agonist that inhibits HIV type 1 infection of human macrophages and activated T cells.

Authors:  Maarten Buitendijk; Susan K Eszterhas; Alexandra L Howell
Journal:  AIDS Res Hum Retroviruses       Date:  2013-02-05       Impact factor: 2.205

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.